Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.
Hosted on MSN23h
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPCAdding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback